SAN DIEGO–(BUSINESS WIRE)—- $EYPT #EYPT–EyePoint allegedly misled investors regarding the efficacy and viability of DURAVYU for the treatment of wet age-related macular degeneration.
SAN DIEGO–(BUSINESS WIRE)—- $EYPT #EYPT–EyePoint allegedly misled investors regarding the efficacy and viability of DURAVYU for the treatment of wet age-related macular degeneration.